476060 — Onconic Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Annual cashflow statement for Onconic Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-15,149	-14,432	1,682	-8,093	15,784
Depreciation
Amortisation
Non-Cash Items	6,976	166	1,327	5,276	-2,051
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-869	-898	670	-5,477	-2,867
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-8,859	-14,964	4,140	-7,841	11,395
Capital Expenditures	-8.55	-2,575	-1,157	-141	-303
Purchase of Fixed Assets
Other Investing Cash Flow Items	—	—	38	70.4	-5,894
Sale of Fixed Assets
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-8.55	-2,575	-1,119	-70.9	-6,197
Financing Cash Flow Items	—	138	114	—	-1,611
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	27,356	25,997	-39.9	19,582	-526
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	18,488	8,455	2,784	12,899	4,046